Trump May Try to Force Drugmakers to Match European Prices

The article suggests that the Trump administration may attempt to force drug manufacturers to match lower European prices in the United States. A federal website notice, which was briefly removed and then reposted, hinted at the possibility of more aggressive pricing policies from the administration. The notice outlined a plan to tie Medicare Part B drug payments to international prices, a strategy known as "most-favored-nation" pricing. This approach would aim to reduce the high costs of prescription drugs in the U.S. by aligning them with the lower prices paid in other developed countries. The potential policy shift comes amid ongoing efforts by the Trump administration to tackle the issue of drug affordability and accessibility for American patients. However, the details and timeline of any such pricing initiatives remain unclear, and the article notes that the administration has faced legal and political challenges in implementing previous drug pricing reforms.